ARCUTIS BIOTHERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.13 USD | +1.75% |
|
+3.17% | +151.70% |
| May. 14 | Arcutis Biotherapeutics Q1 Loss Narrows, Revenue Increases; Shares Jump | MT |
| May. 14 | Earnings Flash (ARQT) ARCUTIS BIOTHERAPEUTICS Posts Q1 Revenue $49.6M | MT |
Chart calendar Arcutis Biotherapeutics, Inc.
e04b8cdabb115a6d4bf9ab8e6816bdc0._5by3RHKKA3nh9N2-b8fW3T-O_YADmFu6AK4WaIQURk.pcSY7Vy6fFzQzaoFj_tJD0yZd4xXalc7gEHeKvF8CUia4Z-7dIVFONPGmg~edcaa1eb4aaa702cd8ef39c3897e875b
Upcoming events on Arcutis Biotherapeutics, Inc.
Past events on Arcutis Biotherapeutics, Inc.
| 2024-05-14 04:30 pm | Q1 2024 Earnings Call |
| 2024-05-13 | Q1 2024 Earnings Release After hours |
| 2024-04-11 02:15 pm | Needham Healthcare Conference |
| 2024-03-10 05:30 pm | American Academy of Dermatology Meeting |
| 2024-03-09 06:25 pm | American Academy of Dermatology Meeting |
| 2024-03-04 02:10 pm | TD Cowen Health Care Conference |
| 2024-02-27 08:30 am | Q4 2023 Earnings Call |
| 2024-02-27 05:50 am | Q4 2023 Earnings Release |
| 2024-02-07 10:00 am | Guggenheim Healthcare Talks Biotechnology Conference - Fireside Chat |
| 2024-01-22 04:30 pm | ZORYVE® FDA Approval Call |
| 2024-01-11 | Winter Clinical Dermatology Conference |
| 2023-12-18 08:30 am | Roflumilast Foam FDA Approval Call |
| 2023-11-07 09:50 am | Guggenheim Securities Inflammation & Immunology Conference |
| 2023-11-03 08:30 am | Q3 2023 Earnings Call |
| 2023-11-03 07:30 am | Q3 2023 Earnings Release |
| 2023-09-19 08:30 am | INTEGUMENT PED Pivotal Phase III Trial Results Call |
| 2023-09-12 02:55 pm | Morgan Stanley Global Healthcare Conference |
| 2023-08-08 04:30 pm | Q2 2023 Earnings Call |
| 2023-08-08 04:02 pm | Q2 2023 Earnings Release |
| 2023-06-13 01:40 pm | Goldman Sachs Global Healthcare Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 3,69 2,88 27.9% | 59,6 57,5 3.73% | 117 |
|
EBITDA Million USD | Released Forecast Spread | -43,1 -49,7 13.29% | -137 -140 2.14% | -206 -205 -0.34% | -301 -309 2.74% | -240 -249 3.6% | -222 |
|
EBIT Million USD | Released Forecast Spread | -43,1 -49,0 11.96% | -137 -139 2.03% | -207 -211 1.92% | -302 -315 4.14% | -241 -249 3.01% | -214 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 0,00 - | -136 -139 2.06% | -206 -215 4.23% | -311 -327 4.73% | -259 -265 2.27% | -229 |
|
Net income Million USD | Released Forecast Spread | 0,00 0,00 - | -136 -139 2.06% | -206 -215 4.23% | -311 -327 4.73% | -262 -267 1.93% | -229 |
|
EPS USD | Released Forecast Spread | 0,00 0,00 - | -3,80 -3,90 2.56% | -4,18 -4,36 4.18% | -5,66 -5,96 4.98% | -3,78 -3,94 4.12% | -2,38 |
| Announcement Date | 19/03/20 | 16/02/21 | 22/02/22 | 28/02/23 | 27/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,73 0,66 9.85% | 2,96 2,05 44.74% | 2,78 3,11 -10.7% | 5,19 4,62 12.42% | 38,1 30,8 23.65% | 13,5 11,4 18.77% | 15,1 | 24,8 | 34,4 | 44,8 |
|
EBITDA Million USD | Released Forecast Spread | -71,2 -75,9 6.26% | -62,5 -70,3 11.13% | -105 -101 -3.66% | -68,3 -77,3 11.69% | -76,1 -73,0 -4.23% | -66,6 | -36,7 -46,0 20.21% | ||||||
|
EBIT Million USD | Released Forecast Spread | -71,3 -82,9 13.98% | -62,6 -74,3 15.67% | -65,8 -72,2 8.88% | -105 -102 -3.05% | -68,4 -82,4 17% | -76,3 -72,8 -4.75% | -66,8 -72,9 8.47% | -36,9 -49,3 25.16% | -61,2 -67,3 9.16% | -62,5 | -53,8 | -46,3 | -37,9 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -71,3 -82,7 13.75% | -64,3 -75,1 14.35% | -67,4 -74,0 8.91% | -108 -111 3.34% | -72,0 -88,1 18.29% | -80,1 -76,6 -4.62% | -71,0 -76,4 7.08% | -41,7 -55,6 24.88% | -66,3 -72,3 8.4% | -67,3 | -58,7 | -51,1 | -43,1 |
|
Net income Million USD | Released Forecast Spread | -71,3 -82,7 13.75% | -64,3 -75,1 14.35% | -67,4 -74,0 8.91% | -108 -104 -3.47% | -72,0 -88,1 18.29% | -80,1 -76,6 -4.62% | -71,0 -76,4 7.08% | -44,8 -55,6 19.44% | -66,3 -71,3 7.04% | -67,3 | -58,7 | -51,1 | -43,1 |
|
EPS USD | Released Forecast Spread | -1,42 -1,60 11.39% | -1,27 -1,49 14.91% | -1,31 -1,43 8.39% | -1,89 -1,88 -0.35% | -1,18 -1,45 18.43% | -1,31 -1,25 -4.52% | -1,16 -1,24 6.45% | -0,73 -0,88 16.57% | -0,72 -0,79 8.57% | -0,73 | -0,67 | -0,55 | -0,47 |
| Announcement Date | 22/02/22 | 05/05/22 | 04/08/22 | 08/11/22 | 28/02/23 | 09/05/23 | 08/08/23 | 03/11/23 | 27/02/24 | - | - | - | - |
| 2024-05-15 | BIOCON LIMITED: Q4 2024 Earnings Release |
| 2024-05-16 09:00 am | ZEALAND PHARMA A/S: Q1 2024 Earnings Release |
| 2024-05-17 07:00 am | AUTOLUS THERAPEUTICS PLC: Q1 2024 Earnings Release |
| 2024-07-23 | VIKING THERAPEUTICS, INC.: Q2 2024 Earnings Release (Projected) |
| 2024-07-24 | BIOCON LIMITED: Q1 2025 Earnings Release (Projected) |
| 2024-07-25 01:00 am | ARGENX SE: Q2 2024 Earnings Release |
| 2024-07-29 | RHYTHM PHARMACEUTICALS, INC.: Q2 2024 Earnings Release (Projected) |
| 2024-07-29 | NEUROCRINE BIOSCIENCES, INC.: Q2 2024 Earnings Release (Projected) |
| 2024-07-29 | CEREVEL THERAPEUTICS HOLDINGS, INC.: Q2 2024 Earnings Release (Projected) |
| 2024-07-30 | CASSAVA SCIENCES, INC.: Q2 2024 Earnings Release (Projected) |
Past sector events for Arcutis Biotherapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ARQT Stock
- Calendar Arcutis Biotherapeutics, Inc.